(Q33339663)

25 July 2017

title

Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients (English)

1 reference

25 July 2017

1 reference

E Lindhoff-Last

1

1 reference

25 July 2017

C Betz

series ordinal

2

1 reference

25 July 2017

R Bauersachs

series ordinal

3

1 reference

25 July 2017

publication date

1 October 2001

1 reference

Clinical and Applied Thrombosis-Hemostasis

25 July 2017

published in

1 reference

25 July 2017

volume

7

1 reference

25 July 2017

issue

4

1 reference

25 July 2017

page(s)

300-304

1 reference

Acute renal failure in the intensive care unit. Therapy overview, patient risk stratification, complications of renal replacement, and special circumstances

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107602960100700409

Continuous renal replacement therapy in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960100700409

Gastrointestinal blood loss in haemodialysis patients during use of a low-molecular-weight heparinoid anticoagulant

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960100700409

Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960100700409

10.1177/107602960100700409

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference